Arquivos_Pdfs_ConsensoPsorase2009
113 pág.

Arquivos_Pdfs_ConsensoPsorase2009

Disciplina:Clínica Médico-cirúrgica I58 materiais1.079 seguidores
Pré-visualização41 páginas
Média de resposta Dose-dependente, após 8-16 semanas com 3mg/kg, PASI 90 em 30 a 50% e PASI 75
em 50-70% dos pacientes

Contraindicações importantes Absolutas: insuficiência renal, hipertensão arterial não controlada, infecções não
controladas, doenças malignas (em atividade ou prévias, particularmente hematológicas
e cutâneas com exceção do carcinoma basocelular)
Relativas: disfunção hepática, gravidez, lactação, uso concomitante de medicações
que interagem com a ciclosporina, uso concomitante de fototerapia ou PUVA terapia
prévia com dosagem cumulativa >1000 J/cm,2 uso concomitante de agentes
imunossupressores, retinoides ou uso prévio, a longo prazo, de metotrexato

Efeitos adversos importantes Insuficiência renal, aumento da pressão arterial, insuficiência hepática,náuseas, anorexia,
vômitos, diarreia, hipertricose, hiperplasia gengival, tremores, parestesias

Interações com drogas importantes Verificar uso de drogas concomitantes

Outros Risco aumentado de carcinoma espinocelular em pacientes de psoríase que receberam
fototerapia excessiva. Moderadamente efetiva e não aprovada para artrite psoriásica

Fonte: Reich C et al 11

CONSENSO BRASILEIRO DE PSORÍASE 2009|SOCIEDADE BRASILEIRA DE DERMATOLOGIA

82 | Ciclosporina na Psoríase

REFERÊNCIAS
1. Lebwohl M, Ellis C, Gottlieb A, et al. Cyclosporine consensus conference: with emphasis on the treatment of psoriasis. J Am

Acad Dermatol. 1998;39:464-75.
2. Griffiths CEM, Dubertret L, Ellis CN et al. Ciclosporin in psoriasis clinical practice: an international consensus statement. Br J

Dermatol. 2004;150:11–23.
3. Dadlani C, Orlow S J. Treatment of children and adolescents with methotrexate, cyclosporine, and etarnecept: Review of the

dermatologic and rheumatologic literature. J Am Acad Dermatol. 2005; 52:316-40.
4. Mueller W, Hermann B: Cyclosporin A for psoriasis. N Engl J Med. 1979;301:555.
5. VanHoof JP, Leunissen KML, Staak WVD. Cyclosporin and psoriasis. Lancet. 1985; 1:335.
6. Ellis CN, Gorsulowsky DC, Hamilton TA, et al. Cyclosporine improves psoriasis in a double-blind study. JAMA.

1986;256:3110-6.
7. Griffiths CEM, Clark CM, Chalmers RJG, et al. A systematic review of treatments for severe psoriasis. Health Technol Assess.

2000;4:40.
8. Berth-Jones J. The use of ciclosporin in psoriasis. J Dermatol Treat. 2005;16:258-77.
9. Smith SG. Neoral (cyclosporin) in dermatology: technical aspects. Br J Dermatol. 1996; 135 (Suppl. 48):2-4.
10. Yosipovitch G, Tang MBY. Pratical management of psoriasis in the elderly. Drugs & Aging. 2002;19:847-63.
11. Reich C, Rosenbach T, Mohr J. Cyclosporine. J Dtsch Dermatol Ges. 2007;5( Suppl 3):36-45.
12. Ho VC. The use of ciclosporin in psoriasis: a clínical review. Br J Dermatol. 2004;150 (Suppl 67):1-10.
13. Mrowietz U, Ruzicka T. Cyclosporin A for psoriasis. Dermatol Ther.1999;11:60–6.
14. Feldman SR, Garton R. Cyclosporin in psoriasis: how?. J Eur Acad Dermatol Venereol. 2004;18:250-3.
15. Naldi L, Griffiths CEM. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment

of the benefits and risks. Br J Dermatol. 2005; 152: 597–615.
16. Lebwohl M, Menter A, Koo J, et al. Combination therapy to treat moderate to severe psoriasis. J Am Acad Dermatol. 2004;

50: 416-30.
17. Paul CF, Ho VC, McGeown C et al. Risk of malignancies in psoriasis treated with cyclosporine: a 5-year cohort study. J Invest.

Dermatol. 2003;120:211–6.
18. Marcil I, Stern RS. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study.

Lancet. 2001; 358: 1042–5.
19. Workshop of the Research Unit of the Royal College of Physicians of London; Department of Dermatology, University of

Glasgow; British Association of Dermatologists. Guidelines for management of patients with psoriasis. BMJ. 1991; 303: 829-35.
20. Koo J, Lee J. Cyclosporine: what clinicians need to know?. Dermatol Clin. 1995;13: 897-907.
21. Lebwohl M. A clinician’s paradigm in the treatment of psoriasis. J Am Acad Dermatol. 2005; 53: S59-69.
22. Aydin F, Canturk T, Senturk N, et al. Methotrexate and ciclosporin combination for the treatment of severe psoriasis. Clin Exp

Dermatol. 2006;31:520–4.
23. Feliciani C, Zampetti A, Forleo P et al. Nail Psoriasis: Combined therapy with systemic cyclosporin and topical calcipotriol.

J Cutan Med Surg. 2004;8:122-5.
24. Davison SC, Morris-Jones R, Powles AV, et al. Change of treatment from cyclosporin to mycophenolate mofetil in severe

psoriasis. Br J Dermatol. 2000;143:405–7.
25. Mrowietz U. Advances in systemic therapy for psoriasis. Clin Exp Dermatol. 2001;26: 362–7.
26. Mrowietz U. Treatment targeted to cell surface epitopes. Clin Exp Dermatol. 2002;27: 591–6.
27. Lima HC, Kubo E, Rosas F, et al. Combining biologics and cyclosporine. Poster 3372. Electronic Posters. Meeting AAD,

San Francisco, 2009.
28. Koo J. Systemic sequential therapy of psoriasis: a new paradigm for improved therapeutic results. J Am Acad Dermatol.

1999;41:S25–8.

Ciclosporina na Psoríase | 83

CONSENSO BRASILEIRO DE PSORÍASE 2009|SOCIEDADE BRASILEIRA DE DERMATOLOGIA

29. Nijsten TE, Stern RS. Oral retinoid use reduces cutaneous squamous cell carcinoma risk in patients with psoriasis treated with
psoralen-UVA: a nested cohort study. J Am Acad Dermatol. 2003; 49: 644–50.

30. Mrowietz U, Christophers E, Altmeyer P. Treatment of severe psoriasis with fumaric acid esters: scientific background and
guidelines for therapeutic use. The German Fumaric Acid Ester Consensus Conference. Br J Dermatol. 1999;141:424–9.

31. Rogers M. Childhood psoriasis. Curr Opin Pediatr. 2002:14:404–9.
32. Morris A, Rogers M, Fischer G, et al. Childhood psoriasis: a clínical review of 1262 cases. Pediatr Dermatol. 2001:18:188–98.
33. Drug Information for the Healthcare Professional - USP DI - Vol.I 21st ed. Englewood, CO: Thomson Health care –

MICROMEDEX, 2001; p. 1137.
34. Tauscher AE, Fleischer AB Jr, Phelps KC et al. Psoriasis and pregnancy. J Cutan Med Surg. 2002;6:561-70.
35. Barker J. Genetic aspects of psoriasis. Clin Exp Dermatol. 2001;26:321–5.
36. Dunna SF, Finlay AY. Psoriasis: improvement during and worsening after pregnancy. Br J Dermatol. 1989;120:584.
37. Boyd AS, Morris LF, Phillips CM et al. Psoriasis and pregnancy: hormone and immune system interaction. Int J Dermatol.

1996;35:169.
38. McHugh NJ, Laurent MR. The effect of pregnancy on the onset of psoriatic arthritis. Br J Rheumatol. 1989;28:50–2.
39. Krueger GG, Feldman SR, Camisa C, et al. Two considerations for patients with psoriasis and their clinicians: what defines

mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am
Acad Dermatol. 2000; 43: 281–5.

40. Spuls PI, Bossuyt PM, van Everdingen JJ, et al. The development of practice guidelines for the treatment of severe
plaque-form psoriasis. Arch Dermatol. 1998;134:1591–6.

41. Feldman S. Advances in psoriasis treatment. Dermatol Online J. 2000;6:4.
42. Koo YM. Current consensus and update on psoriasis therapy: a perspective from the United States. J Dermatol.

1999;26:723–33.
43. Imai N, Watanabe R, Fujiwara H, et al. Successful treatment of impetigo herpetiformis with oral cyclosporine during

pregnancy. Arch Dermatol. 2002;138:128-9.
44. Finch TM, Tan CY. Pustular psoriasis exacerbated by pregnancy and controlled by cyclosporin A. Br J Dermatol.

2000;142:582-4.
45. Koo YM. Current consensus and update on psoriasis therapy: a perspective from the United States. J Dermatol.

1999;26:723–33.
46. Grossman RM, Chevret S, Abi-Rached J, et al. Long term safety of cyclosporine in the treatment of psoriasis. Arch Dermatol.

1996;132:623-9.
47. Griffiths CE. Systemic and local administration of cyclosporine in the treatment of psoriasis. J Am Acad Dermatol.

1990;23:1242-7.
48. Bonifati C, Carducci M, Mussi A, et al. Recognition and treatment of psoriasis. Special considerations in elderly patients. Drugs

& Aging. 1998;12:177-90.
49. Lebwohl M, Ali S. Treatment of